Listed by the USPTO as EVANS, CHRISTOPHER RYAN
Tech Center 1600 • Art Units: 1677 1678
This examiner grants 61% of resolved cases
EVANS, CHRISTOPHER RYAN is assigned to technology center 1600 and art unit 1677. The profile includes 23 resolved cases, a 60.9% allowance rate, a 64.3% interview lift, and a median of 1413 days to allowance. The interview measure is the most pronounced feature of the record, while the limited case volume calls for careful interpretation.
Abbott Laboratories, Genentech Inc., and Denso Corporation appear among the listed companies. The associated firms are CANTOR COLBURN LLP - UCONN, CASIMIR JONES, S.C, and HARNESS DICKEY (DETROIT). The data supports prioritizing examiner interviews when preparing responses, while the median timing indicates that applicants should allow substantial time for prosecution. The allowance rate provides useful context, but the small resolved-case base limits its predictive reach.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18045845 | METHODS AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF AN ANTI-B-CORONAVIRUS ANTIBODY IN A SAMPLE | Non-Final OA | Abbott Laboratories |
| 17503122 | ANTIBODY POTENCY ASSAY | Final Rejection | Genentech, Inc. |
| 18677132 | ANALYSIS METHOD | Non-Final OA | DENSO CORPORATION |
| 17495133 | METHOD OF AMPLIFYING FLUORESCENT SIGNAL THROUGH CYCLIC STAINING OF TARGET MOLECULES VIA FLUOROPHORE-CONJUGATED COMPLEMENTARY ANTIBODIES | Final Rejection | Korea Advanced Institute Of Science And Technology |
| 17954999 | ASSAYS TO QUANTITATE DRUG AND TARGET CONCENTRATIONS | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18698098 | FC-GAMMA RECEPTOR II BINDING AND GLYCAN CONTENT | Non-Final OA | AMGEN INC. |
| 18138888 | TARGET TISSUE-SPECIFIC ANTIGEN-BINDING MOLECULE | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18351317 | ULTRASENSITIVE SENSING METHOD FOR DETECTION OF BIOMOLECULES | Non-Final OA | University of Connecticut |
| 18432550 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | Non-Final OA | AJINOMOTO CO., INC. |
| 17997435 | METHODS OF IDENTIFYING MODULATORS OF THE IL-17 PATHWAY | Non-Final OA | Janssen Pharmaceutica NV |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy60.9% of resolved applications examined by Christopher Ryan Evans were allowed (23 resolved cases), compared with 32.7% across Art Unit 1677 over the last five years.
This examiner's interview lift is +64.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Christopher Ryan Evans took 1,413 days on average from filing to allowance.
Christopher Ryan Evans examines applications in Art Unit 1677 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
